Erratum: AACE Obesity Position Statement (Endocrine Practice (2012) 18 (642-648))

摘要

I received an anonymous and vitriolic letter concerning a Conflict of Interest Statement by Dr. W. Timothy Garvey related to the AACE Obesity Position Statement published in Endocrine Practice 2012;18:642-648. Dr. Garvey was 1 of 4 primary writers and had correctly stated his "Conflict of Interest Statement" as having "a significant financial relationship that might pose a multiplicity of interest for this article." This statement reads as followsr. "Performed registered clinical trials research for phentermine/topiramate ER by Vivus, member of several ad hoc advisory boards for Vivus, authorship of peer-reviewed clinical trials publications for phentermine/topiramate ER, advisory board member for Alkermes, advisory board member for Daiichi-Sankyo, Merck speaker list." This signed statement was submitted by Dr. Garvey to Endocrine Practice on 9/25/12 and was inadvertently omitted from the published manuscript. We apologize to Dr. Garvey and our readers for this unfortunate omission.